BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more

Ovid’s gaboxadol meets in Phase II for Fragile X   Ovid Therapeutics Inc. (NASDAQ:OVID) said gaboxadol (OV101) met its primary safety endpoint and reduced behavioral and functional symptoms in the Phase II ROCKET trial to...
BioCentury | Feb 18, 2020
Product Development

Riptide peptide turns TAMs proinflammatory

Riptide has lifted the curtain on its first immuno-oncology program, RP-182, which comprises an engineered peptide that reprograms tumor-associated macrophages to become proinflammatory. Strategies to convert immunosuppressive macrophages into proinflammatory cells have been gaining momentum...
BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Extra | Nov 4, 2019
Clinical News

Halozyme to focus on Enhanze partnering after Phase III oncology miss

With the failure of Halozyme's lead cancer program in a Phase III trial, the company intends to exit the oncology R&D field entirely and focus on deriving partner revenue from its subcutaneous drug delivery technology...
BC Innovations | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BC Extra | Sep 30, 2019
Clinical News

Seattle Genetics, Astellas ADC posts strong response in bladder combo study at ESMO

As enfortumab vedotin awaits regulatory action to treat advanced bladder cancer, Seattle Genetics and partner Astellas showed impressive combination data for the antibody-drug conjugate that could quickly move the molecule even earlier in the disease....
BC Extra | Sep 27, 2019
Clinical News

Incyte lining up pemigatinib filing on ESMO data

With updated data presented at ESMO, Incyte said it will submit an NDA to FDA this year to seek accelerated approval of its FGFR inhibitor in a niche cancer indication of cholangiocarcinoma. The biotech also...
BC Week In Review | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib and Tomudex...
BC Extra | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial  Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve mean Best Corrected Visual Acuity (BCVA) at three months, the primary...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

LIF inhibition sensitizes pancreatic cancer to chemotherapy

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting LIF could sensitize KRAS-driven pancreatic cancer to chemotherapy. LIF levels were higher in two human pancreatic ductal adenocarcinoma (PDAC) cell lines with KRAS-activating mutations than in a cell...
Items per page:
1 - 10 of 1235